Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers

Details for Australian Patent Application No. 2009209594 (hide)

Owner Novartis AG

Inventors Petersen, Holger; Ahlheim, Markus

Agent Davies Collison Cave

Pub. Number AU-A-2009209594

PCT Pub. Number WO2009/095450

Priority 08150826.9 30.01.08 EP

Filing date 29 January 2009

Wipo publication date 6 August 2009

International Classifications

A61K 9/00 (2006.01) Medicinal preparations characterised by special physical form

A61K 9/06 (2006.01) Medicinal preparations characterised by special physical form - Ointments

A61K 9/10 (2006.01) Medicinal preparations characterised by special physical form - Dispersions

A61K 9/16 (2006.01) Medicinal preparations characterised by special physical form - Agglomerates

A61K 38/31 (2006.01) Medicinal preparations containing peptides - Somatostatins

A61K 47/34 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds

Event Publications

5 August 2010 PCT application entered the National Phase

  PCT publication WO2009/095450 Priority application(s): WO2009/095450

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009209598-Treatment of microbial infections

2009209591-Muteins of tear lipocalin having affinity to human c-Met receptor tyrosine kinase and methods for obtaining the same